truenorthnewsandcommentary.com

It seems that in the old legacy media, whether or not political behavior is objectionable depends not on the behavior itself, but on whose behavior it is.

For example, maybe you missed this report from Byron York over the weekend.  In a commentary – a commentary! – about the Obama administration’s attacks on Fox News, Ken Rudin, NPR’s political director, first said this:

“It’s not only aggressive, it’s almost Nixonesque,” Rudin said. “I mean, you think of what Nixon and Agnew did with their enemies list and their attacks on the media; certainly Vice President Agnew’s constant denunciation of the media. Of course, then it was a conservative president denouncing a liberal media, and of course, a lot of good liberals said, ‘Oh, that’s ridiculous. That’s an infringement on the freedom of press.’ And now you see a lot of liberals almost kind of applauding what the White House is doing to Fox News, which I think is distressing.”

This week,  California First Lady Maria Shriver is taking a seat on the Today Show couch and talking about the “new world” for women in the United States.  She has just released  “The Shriver Report” which offers empirical research about family life, working life, and the

Shriver on Today's Women

constant balancing act that is a reality for women who try, or need to be part of both worlds.

Maria Shriver is a good reporter and always has been.  Now she adds to her perspective, enormous life experience as a mother of four, a front row seat in political life, and eight years as a Governor’s wife touring the communities of California.

I highly encourage viewing her segments airing on the NBC Evening News, or Today, or MSNBC this week.  There is a lot to learn from her reports. It is valuable to know the source of the research as well.  The American Policy Institute, partnering with TIME Magazine, conducted polling of 3,413 people throughout the U.S.  Both men and women were polled in the study.   For your information, former Clinton aide, John Podesta, is the head of the American Policy Institute.  Scanning the initial findings, the results are telling.

Broadcasters and pundits ccould be a bit more kind in their reviews of President Obama’s surprise Nobel Peace Prize.  He IS the first

Making Peace

African American to sit in the White House.  It is odd that, according to CNN, the Nobel Committee closed nominations shortly after Obama was inaugurated.  His “peace” efforts were still wet ink droplets on the page at that time.

In any event, Barack Obama will give the money to charity, all $1.4 million of it, which after taxes will be something over $700,000.  Donating the balance to charity will shelter the remainder of his government salary this year!  Those are the realities.

Past Peace Prize recipients include Al Gore, Henry Kissenger, Jimmy Carter, and of course Martin Luther King.  I thought it might be interesting to remember the names and acts of women  who have been recognized with the Nobel Peace Prize .  Turns out there’s a lot of politics…..in peace.

Thanks to Instapundit, I saw this graph from Don Suber’s site:

Glenn Reynolds‘ comment:  “Not living up to the promises they made, is it? But don’t worry, health care will be totally different.“

Chemotherpay at Duke Cancer Clinic

This article in today’s Salt Lake City Deseret News is so vital and informational to those who have or who are or who will confront Cancer in their families, that True North takes the opportunity to excerpt it here and thanks writer Lois M. Collins for her great piece and for spreading the news of the work of Massachusetts firm,  Merrimack Pharmaceuticals, for their innovatoins in Cancer research.

FIRM TAKES ENGINEERING APPROACH TO TREATING CANCER

A Massachusetts company with strong Utah ties is approaching the finding and fixing of cancerous tumors as an engineering challenge. It believes most solid tumors are triggered by one or more of six distinct systemic signaling-mechanism breakdowns and it’s developing treatments to repair them.

Merrimack Pharmaceuticals of Cambridge, Mass., on Thursday announced a $530 million exclusive worldwide licensing agreement with French pharmaceutical giant sanofi-aventis for the development and co-commercialization of a drug targeting the first of those

signaling breakdowns.